Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus prednisone vs placebo plus prednisone in newly diagnosed moderate to severe chronic GVHD
CTR20180639Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ibrutinib in chronic graft-versus-host disease (cGVHD), sponsored by Janssen Pharmaceutical. Started May 2018; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on CTR20180639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180639.